EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Novel insights of EZH2-mediated epigenetic modifications in degenerative musculoskeletal diseases

Zetao Ma, Lei Chen, Yushun Wang, Sheng Zhang, Jianrui Zheng, Yuhong Luo, Chao Wang, Hui Zeng, Lixiang Xue, Zhen Tan, Deli Wang

Ageing Research Reviews · 2023-09 · 90 · 102034

DOI: 10.1016/j.arr.2023.102034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2023-09. Verfasst von Zetao Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone and Joint Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, People's Republic of China. Hauptthemen laut MEDLINE: Histones, Osteoarthritis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 121 Literaturangaben. Gefördert von: Science, Technology and Innovation Commission of Shenzhen Municipality, Shenzhen Science and Technology Innovation Program, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Degenerative musculoskeletal diseases (Osteoporosis, Osteoarthritis, Degenerative Spinal Disease and Sarcopenia) are pathological conditions that affect the function and pain of tissues such as bone, cartilage, and muscles, and are closely associated with ageing and long-term degeneration. Enhancer of zeste homolog 2 (EZH2), an important epigenetic regulator, regulates gene expression mainly through the PRC2-dependent trimethylation of histone H3 at lysine 27 (H3K27me3). Increasing evidence suggests that EZH2 is involved in several biological processes closely related to degenerative musculoskeletal diseases, such as osteogenic-adipogenic differentiation of bone marrow mesenchymal stem cells, osteoclast activation, chondrocyte functional status, and satellite cell proliferation and differentiation, mainly through epigenetic regulation (H3K27me3). Therefore, the synthesis and elucidation of the role of EZH2 in degenerative musculoskeletal diseases have attracted increasing attention. In addition, although EZH2 inhibitors have been approved for clinical use, whether they can be repurposed for the treatment of degenerative musculoskeletal diseases needs to be considered. Here, we reviewed the role of EZH2 in the development of degenerative musculoskeletal diseases and brought forward prospects of its pharmacological inhibitors in the improvement of the treatment of the diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HistonesOsteoarthritisHumansEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticAging

Stichwörter der Autor:innen

Degenerative musculoskeletal diseaseEZH2EZH2 inhibitorEpigenesis

Substanzen

HistonesEnhancer of Zeste Homolog 2 ProteinEZH2 protein, human

Autor:innen und Institutionen

  • Department of Bone and Joint Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, People's Republic of China.
  • Department of Bone and Joint Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, People's Republic of China; Shantou University Medical College, Shantou 515031, People's Republic of China.
  • Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, People's Republic of China. Electronic address: lixiangxue@bjmu.edu.cn.
  • Department of Bone and Joint Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, People's Republic of China. Electronic address: tanzeric@bjmu.edu.cn.
  • Department of Bone and Joint Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, People's Republic of China. Electronic address: wangdeliORTHO@outlook.com.

Förderung

  • Science, Technology and Innovation Commission of Shenzhen Municipality
  • Shenzhen Science and Technology Innovation Program
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • National Natural Science Foundation of China

Zitieren

APA

Ma, Z., Chen, L., Wang, Y., Zhang, S., Zheng, J., Luo, Y., Wang, C., Zeng, H., Xue, L., Tan, Z., & Wang, D. (2023). Novel insights of EZH2-mediated epigenetic modifications in degenerative musculoskeletal diseases. Ageing Research Reviews, 90, 102034. https://doi.org/10.1016/j.arr.2023.102034

Vancouver

Ma Z, Chen L, Wang Y, Zhang S, Zheng J, Luo Y, et al. Novel insights of EZH2-mediated epigenetic modifications in degenerative musculoskeletal diseases. Ageing Research Reviews. 2023;90:102034. doi:10.1016/j.arr.2023.102034

BibTeX
@article{Ma2023,
  author = {Ma, Zetao and Chen, Lei and Wang, Yushun and Zhang, Sheng and Zheng, Jianrui and Luo, Yuhong and Wang, Chao and Zeng, Hui and Xue, Lixiang and Tan, Zhen and Wang, Deli},
  title = {Novel insights of EZH2-mediated epigenetic modifications in degenerative musculoskeletal diseases},
  journal = {Ageing Research Reviews},
  year = {2023},
  volume = {90},
  pages = {102034},
  doi = {10.1016/j.arr.2023.102034}
}
Kostenlos starten →